IP Library Granted Patent US 9,624,155
Granted Patent B2
US 9,624,155 · App. 14/184,062 · Granted Apr 18, 2017

Iron (III) citrate, substantially free of beta-iron hydroxide oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,155
App. No.
14/184,062
Granted
Apr 18, 2017
Kind
B2
Abstract

This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof.

Claims (19)

1. A method for producing iron(III) citrate comprising:

a step of forming an iron-containing precipitate comprising bringing ferric chloride into contact with sodium hydroxide in an aqueous medium for a duration of two hours or less at a liquid temperature of 0° C. to 10° C. to form an iron-containing precipitate;

a step of generating an aqueous solution of iron(III) citrate comprising bringing citric acid into contact with the iron-containing precipitate in an aqueous medium and generating an aqueous solution of iron(III) citrate via heating; and

a step of precipitating iron(III) citrate comprising bringing the aqueous solution of iron(III) citrate into contact with an organic solvent to precipitate the iron(III) citrate.

2. The method according to claim 1 , wherein the step of generating an aqueous solution of iron(III) citrate comprises bringing citric acid into contact with the iron-containing precipitate at a liquid temperature of 60° C. to 100° C.

3. The method according to claim 1 , wherein the iron-containing precipitate is ferrihydride.

4. The method according to claim 1 , wherein the duration during which ferric chloride is in contact with sodium hydroxide is one hour or less.

5. The method according to claim 1 , wherein the duration during which ferric chloride is in contact with sodium hydroxide is 30 minutes or less.

6. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of lower than 10° C.

7. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 3.5° C. to 8° C.

8. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 2.6° C. to 7.5° C.

9. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 2.6° C. to 7.6° C.

10. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 0° C. to 7.3° C.

11. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 1.3° C. to 8.3° C.

12. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 2.5° C. to 8.4° C.

13. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 1.9° C. to 8.0° C.

14. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 1.4° C. to 8.3° C.

15. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 2.2° C. to 9.1° C.

16. The method according to claim 1 , wherein the step of forming an iron-containing precipitate comprises bringing ferric chloride into contact with sodium hydroxide in an aqueous medium at a liquid temperature of 3.0° C. to 5.3° C.

Assignments (18)
CHANGE OF ADDRESS Recorded Apr 8, 2026
From: JAPAN TOBACCO INC.
To: JAPAN TOBACCO INC.
Reel/Frame 075366/0624 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 25, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 067839/0134 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 29, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 066377/0741 →
FIFTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 4, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066205/0143 →
THIRTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 29, 2023
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063189/0065 →
TWELFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 062012/0561 →
ELEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 22, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 061297/0238 →
TENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 16, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 060529/0168 →
SECURITY INTEREST Recorded Dec 15, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058399/0055 →
SEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 12, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 057474/0770 →
SIXTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 11, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 056544/0468 →
CHANGE OF ADDRESS Recorded Apr 9, 2021
From: JAPAN TOBACCO INC.
To: JAPAN TOBACCO INC.
Reel/Frame 056797/0633 →
FIFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 30, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 055776/0491 →
FOURTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 17, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054793/0455 →
THIRD AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 10, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054173/0451 →
SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 053671/0221 →
SECURITY INTEREST Recorded Apr 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052295/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2016
From: ANDO, KOJI; MANTA, NAOKI
To: JAPAN TOBACCO INC.
Reel/Frame 040535/0390 →